Skip to main content

Table 1 Characteristics of targets and primary antibodies used in the study

From: In-vitro effects of the antimicrobial peptide Ala8,13,18-magainin II amide on isolated human first trimester villous trophoblast cells

Antigen

Specification of antibody

Final concentration

Purpose*

β-actin

Sheep IgGa

2.0 μg/ml

Internal normalization control, used in WB

Cytokeratin 7

Mouse IgGb

6 μg/ml

Epithelial cell marker, used in ICC

Cytokeratin 18 neo-epitope (CK18f)

Mouse IgGc

1:50 (WB); 1:20 (ICC)

Early apoptosis marker, used in WB and ICC

βhCG

Rabbit IgGc

4 μg/ml (WB); 10 μg/ml (ICC)

CTB differentiation marker, used in WB and ICC

hPL Goat IgGd

 

3 μg/ml (WB); 7 μg/ml (ICC)

CTB differentiation marker, used in WB and ICC

Vimentin

Mouse IgGa

3 μg/ml

Cytoskeletal protein marker for fibroblasts, used in ICC

Vitronectin receptor, Integrin αVβ3 (CD51)

Mouse IgGe

10 μg/ml

Invasive CTB marker, used in ICC

von Willebrand factor

Rabbit IgGc

25 μg/ml

Endothelial cell marker (in Weibel-Palade bodies), used in ICC

  1. *see references [17–19, 23–27, 32] for details.
  2. CTB, cytotrophoblast cells. ICC, immunocytochemistry. WB, Western blot analysis.
  3. aR&D Systems, Minneapolis. bSigma Chemical, St Louis, MO, USA. cDako, Glostrup, Denmark. dSanta Cruz Biotechnology, Santa Cruz, CA, USA. eZymed Laboratories, San Francisco, CA, USA.